BASIC AND CLINICAL EVALUATION OF MEROPENEM
スポンサーリンク
概要
- 論文の詳細を見る
Meropenem (MEPM) is a newly developed carbapenem antibiotic for parenteral use. We performed basic and clinical evaluations of MEPM, and obtained the following results.<BR>1. MEPM showed potent antibacterial activity against ampicillin-resistant <I>Escherichia coli</I> and beta-lactamase producing <I>Pseudomonas aeruginosa</I>. Activity was hardly influenced by the increase of inoculum size.<BR>2. MEPM was well distributed in 6 healthy male volunteers. The peak level after drip infusion was 25.7±6.12 μg/ml and the serum half-life for the beta phase was 1.18±0.12 h. The urinary recovery of MEPM up to 8 hours after infusion was 57.6±8.77% of total dose.<BR>The effect of probenecid was observed to determine the existence of renal tubular secretion of MEPM. Coadministration of probenecid resulted in increases in serum half life (1.18±0.12→1.33±0.14 h) and area under the curve (28.1+3.55→40.2+3.76 μg/ml) and decreases in distribution volume (20.2±3.23→19.5+1.48 1) and total clearance (18.0+2.17→12.5±1.16 1/h). All of these changes were statistically significant. These data indicate that renal tubular secretion plays some part in the renal excretion of MEPM.<BR>3. MEPM was administered to nine patients, 1 with sepsis, 2 with bacterial pneumonia, 2 with bronchitis, 1 with acute exacerbation of chronic RTI, 1 with acute exacerbation of chronic diffuse panbronchiolitis, 1 with bacterial peritonitis and 1 complicated with urinary tract infection. The MEPM dose was 0.25 to 0.5g per infusion, once or twice per day for 8 to 18 days. The clinical response was excellent in 5 patients, good in 3 patients and fair in one patient. No side effects, subjective and/or objective symptoms, were observed. In 3 patients we observed increased transamidase level in blood, and in one patient, decreased creatinine clearance.
論文 | ランダム
- 映画化始末 (筒井康隆の逆襲--超虚構実験小説の展開)
- 一輪花の咲けかしと--透谷と藤村・一関前後
- うらなりの声--小林信彦『うらなり』にふれて
- 〈夕暮れ〉の与謝野晶子--『みだれ髪』を中心に
- 「くれがた」の暮鳥--伝統と同時代のなかで